Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19955828rdf:typepubmed:Citationlld:pubmed
pubmed-article:19955828lifeskim:mentionsumls-concept:C1413791lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C0009780lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C0151650lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C1621966lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:19955828lifeskim:mentionsumls-concept:C1363844lld:lifeskim
pubmed-article:19955828pubmed:issue3lld:pubmed
pubmed-article:19955828pubmed:dateCreated2010-2-22lld:pubmed
pubmed-article:19955828pubmed:abstractTextConnective tissue growth factor (CTGF, CCN2) is a key mediator of tissue fibrosis. CCN2 plays an important role in the development of glomerular and tubulointerstitial fibrosis in progressive kidney diseases. In this review, we discuss the biology of CCN2 with a focus on the regulation of CCN2 gene, cellular mechanisms of profibrotic CCN2 effects and the current in vivo and in vitro evidence for the role of CCN2 in the development of renal fibrosis. We also discuss the therapeutic potential of targeting CCN2 for the treatment of renal fibrosis.lld:pubmed
pubmed-article:19955828pubmed:languageenglld:pubmed
pubmed-article:19955828pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19955828pubmed:citationSubsetIMlld:pubmed
pubmed-article:19955828pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19955828pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19955828pubmed:statusMEDLINElld:pubmed
pubmed-article:19955828pubmed:issn1660-2129lld:pubmed
pubmed-article:19955828pubmed:authorpubmed-author:WoodM TMTlld:pubmed
pubmed-article:19955828pubmed:authorpubmed-author:PhanishMysore...lld:pubmed
pubmed-article:19955828pubmed:authorpubmed-author:DockrellM E...lld:pubmed
pubmed-article:19955828pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19955828pubmed:volume114lld:pubmed
pubmed-article:19955828pubmed:ownerNLMlld:pubmed
pubmed-article:19955828pubmed:authorsCompleteYlld:pubmed
pubmed-article:19955828pubmed:paginatione83-92lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:meshHeadingpubmed-meshheading:19955828...lld:pubmed
pubmed-article:19955828pubmed:year2010lld:pubmed
pubmed-article:19955828pubmed:articleTitleConnective tissue growth factor-(CTGF, CCN2)--a marker, mediator and therapeutic target for renal fibrosis.lld:pubmed
pubmed-article:19955828pubmed:affiliationSW Thames Institute for Renal Research, St. Helier Hospital, London, UK. mysore.phanish@esth.nhs.uklld:pubmed
pubmed-article:19955828pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19955828pubmed:publicationTypeReviewlld:pubmed
entrez-gene:1490entrezgene:pubmedpubmed-article:19955828lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19955828lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19955828lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19955828lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19955828lld:pubmed